SecurityTIF / Tiffany & Co. (886547108)
IndustryJewelry Stores
Common Stock Shares Outstanding124,500,000 shares (as of 2018-01-31)
Total Insiders32
Total Directors15
Total Officers17

Stock Insider Trading (from SEC Form 4)

Tiffany & Co. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

TIF / Tiffany & Co. insiders include Cumenal Frederic, Erceg Mark J, MARQUIS CHARLES K., TRIAN FUND MANAGEMENT, L.P., Galtie Philippe, NICOLETTI RALPH J, MAY PETER W, Davey Andrea, Qatar Investment Authority, and Qatar Holding USA LLC Trapani Francesco, FARAH ROGER N, BERGER GROSS VICTORIA, Cloud Pamela H, BRAVO ROSE MARIE, LILLIE JAMES E, De Winter Jennifer, NAGGIAR CAROLINE D, Hart Andrew W., Barresi John S, FISH LAWRENCE K, COSTLEY GARY E, Bellaiche Jean-Marc, Harlan Leigh M., KOHNSTAMM ABBY F, Singer Robert S, KOWALSKI MICHAEL JOSEPH, Bogliolo Alessandro, PETTERSON JOHN S, Rinaldo Michael D, Koback-Pursel Gretchen, SHUTZER WILLIAM A, .

Insider Roster

Insider Dir Off 10% Shares Owned
NAGGIAR CAROLINE D SENIOR VICE PRESIDENT
X
Trapani Francesco Director
X 446,156
FARAH ROGER N Director
X 21,156
FISH LAWRENCE K Director
X 34,511
LILLIE JAMES E Director
X 22,156
Hart Andrew W. SENIOR VICE PRESIDENT
X 10,065
Davey Andrea Senior Vice President
X 4,029
Cloud Pamela H SENIOR VICE PRESIDENT
X 30,412
Harlan Leigh M. SENIOR VICE PRESIDENT
X 5,328
Bellaiche Jean-Marc SENIOR VICE PRESIDENT
X 6,611
Koback-Pursel Gretchen Senior Vice President
X 2,118
Rinaldo Michael D VP-CONTRLR PRINC. ACCTG. OFF
X
KOWALSKI MICHAEL JOSEPH Director
X 111,870
Singer Robert S Director
X 15,061
Galtie Philippe Senior Vice President
X 3,539
COSTLEY GARY E Director
X 10,962
KOHNSTAMM ABBY F Director
X 31,962
Erceg Mark J Principal Financial Officer
X
Bogliolo Alessandro Chief Executive Officer, Director
X X
MARQUIS CHARLES K. Director
X 134,662
BRAVO ROSE MARIE Director
X
SHUTZER WILLIAM A Director
X
Qatar Holding USA LLC 10% Owner
Qatar Investment Authority 10% Owner
X 11,822,436
De Winter Jennifer Senior Vice President
X
BERGER GROSS VICTORIA SENIOR VICE PRESIDENT
X
Barresi John S VP-PRINC. ACCTG. OFF
X
TRIAN FUND MANAGEMENT, L.P. Director
MAY PETER W
X
PETTERSON JOHN S SENIOR VICE PRESIDENT
X
Cumenal Frederic Chief Executive Officer, Director
X X
MAY PETER W Director
TRIAN FUND MANAGEMENT, L.P. Director
X
NICOLETTI RALPH J PRINCIPAL FINANCIAL OFFICER
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-04-03 4 Trapani Francesco By Argenta Holdings Sarl P I 94.13 30,000 446,156 41,996,664
2018-04-02 4 Trapani Francesco By Argenta Holdings Sarl P I 97.8709 5,000 416,156 40,729,562
2018-03-28 4 FISH LAWRENCE K S D 98.5679 -6,000 34,511 3,401,677
2018-03-29 4 Trapani Francesco By Argenta Holdings Sarl P I 98.4206 5,000 411,156 40,466,220
2018-03-28 4 Trapani Francesco By Argenta Holdings Sarl P I 98.6719 5,000 406,156 40,076,184
2018-03-27 4 FARAH ROGER N By Family Trust P I 97.6628 10,000 21,156 2,066,154
2018-03-26 4 FISH LAWRENCE K S D 97.0243 -3,028 40,511 3,930,551
2018-03-23 4 LILLIE JAMES E P D 96.5853 1,158 22,156 2,139,944
2018-03-23 4 LILLIE JAMES E P D 95.857 3,842 20,998 2,012,805
2018-03-23 4 Hart Andrew W. S D 96.4585 -776 10,065 970,855
2018-03-21 4 Bellaiche Jean-Marc F D 97.97 -1,820 6,611
2018-03-21 4 Bellaiche Jean-Marc M D 3,418 8,431
2018-03-21 4 Hart Andrew W. F D 97.97 -1,491 10,841
2018-03-21 4 Hart Andrew W. M D 3,044 12,332
2018-03-21 4 Harlan Leigh M. F D 97.97 -1,131 5,328
2018-03-21 4 Harlan Leigh M. M D 2,297 6,459
2018-03-21 4 Cloud Pamela H F D 97.97 -1,327 30,412
2018-03-21 4 Cloud Pamela H M D 3,471 31,739
2018-03-21 4 NAGGIAR CAROLINE D F D 97.97 -1,001 19,096
2018-03-21 4 NAGGIAR CAROLINE D M D 2,617 20,097
2018-03-19 4 Davey Andrea F D 97.26 -137 4,029
2018-03-19 4 Davey Andrea M D 405 4,166
2018-03-18 4 Davey Andrea F D 97.26 -146 3,761
2018-03-18 4 Davey Andrea M D 439 3,907
2018-03-16 4 Davey Andrea F D 97.5749 -182 3,468
2018-03-16 4 Davey Andrea M D 534 3,650
2018-03-15 4 Davey Andrea F D 102.27 -157 3,116
2018-03-15 4 Davey Andrea M D 8 3,273
2018-03-15 4 Davey Andrea M D 415 3,265
2018-03-23 4 Trapani Francesco By Argenta Holdings Sarl P I 95.8978 5,000 401,156 38,469,978
2018-03-23 4 Trapani Francesco By Argenta Holdings Sarl P I 96.3325 5,000 396,156 38,162,698
2018-03-22 4 Trapani Francesco By Argenta Holdings Sarl P I 97.3809 5,000 391,156 38,091,123
2018-03-21 4 Trapani Francesco By Argenta Holdings Sarl P I 98.5548 5,000 386,156 38,057,527
2018-03-20 4 Trapani Francesco By Argenta Holdings Sarl P I 98.399 5,000 381,156 37,505,369
2018-03-21 4 LILLIE JAMES E P D 97.8099 5,000 17,156 1,678,027
2018-03-19 4 Koback-Pursel Gretchen F D 97.26 -92 2,118
2018-03-19 4 Koback-Pursel Gretchen M D 270 2,210
2018-03-19 4 Harlan Leigh M. F D 97.26 -42 4,162
2018-03-16 4 Harlan Leigh M. F D 97.5749 -721 4,204
2018-03-16 4 Harlan Leigh M. M D 37 4,925
2018-03-16 4 Harlan Leigh M. M D 1,848 4,888
2018-03-18 4 Koback-Pursel Gretchen F D 97.26 -120 1,940
2018-03-18 4 Koback-Pursel Gretchen M D 352 2,060
2018-03-16 4 Koback-Pursel Gretchen F D 97.5749 -145 1,708
2018-03-16 4 Koback-Pursel Gretchen M D 427 1,853
2018-03-15 4 Koback-Pursel Gretchen F D 102.27 -93 1,426
2018-03-15 4 Koback-Pursel Gretchen M D 5 1,519
2018-03-15 4 Koback-Pursel Gretchen M D 277 1,514
2018-02-28 4 KOWALSKI MICHAEL JOSEPH S D 102.5287 -3,806 111,870 11,469,886
2018-02-23 4 KOWALSKI MICHAEL JOSEPH S D 104.1083 -39,809 115,676 12,042,832
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Tiffany & Co: Overvalued Since 2018

17h seekingalpha
Tiffany & Co. is an overvalued company with a management team that does not understand its own target audience. (5-0)

Spotlight On Gambling Reset And Banking Bill

2018-05-19 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (826-0)

7 Stocks to Buy for Big May Dividend Hikes

2018-04-20 investorplace
While most income investors are reaching for big yields right now, a small group of “hidden yield” stocks are quietly handing smart investors growing income streams plus annual returns of 12%, 27.1% and even 54% or more per year. (53-0)

Atlassian: A Necessary Cooldown

2018-04-20 seekingalpha
Despite beating expectations for Q3 revenues and EPS, Atlassian shares sunk 7% in after-hours trading after reporting results. (38-0)

My Fiancé Wants A Rock For Her Birthday: I'm Buying A Thousand Shares Of Tiffany And Letting Them Pay For It

2018-04-18 seekingalpha
With its new talented CEO Alessandro Bogliolo and a new growth strategy, the company is set for another 5 to 10 years of market outperformance. (5-0)